Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viatris Recalls Semglee Batch Citing Missing Labels

Voluntary Recall Comes As Company Fears Administration Of Wrong Insulin

Executive Summary

Viatris has voluntarily recalled one batch of its Semglee (insulin glargine) pre-filled pens due to the potential for the label to be missing on some pre-filled pens within a labelled carton. The company said that it will arrange for the return of all recalled products. 

You may also be interested in...



Viatris CEO Talks Integration, Roadmap And Interchangeable Biosimilars

As CEO Michael Goettler provides an update on the progress made by Viatris in its first year as a combined company, he also offers Generics Bulletin hints as to the detailed strategy that will be unveiled at the firm’s upcoming investor day and explains how biosimilars – including interchangeable Semglee (insulin glargine) – and complex generics are important components of the firm’s future growth plans.

Kelix Strikes A Deal To Acquire 14 Oncology Injectables

Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.

Cipla And mAbxience Partner For Essential Biosimilars In South Africa

Cipla has partnered with mAbxience to supply oncology and respiratory-related biosimilars on the WHO model list of essential medicines to South Africa.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel